Acquisition Opportunity ZenBio has been acquired by BioIVT as of August 2024, presenting an entry point for BioIVT’s existing customer base to consolidate or expand joint offerings in cell-based products and services.

Cell-based Expertise As a pioneer in adipose derived stem cells and human primary cell culture solutions, ZenBio offers specialized capabilities that can complement contract research, drug discovery, and cosmetic/personal care product testing pipelines.

Revenue Profile Current revenue range is modest (0 to 1 million), indicating potential for growth through higher-margin cell culture reagents, services, or expanded contract research arrangements with larger partners.

Target Markets Active focus across life science research, cosmetics, and personal care sectors creates cross-sell opportunities with biotech suppliers, CROs, and cosmetic testing firms seeking validated human cell systems.

Tech & Capabilities Established tech stack and core offerings in human cell systems provide a foundation for selling scalable cell culture products, custom services, and potential integration with BioIVT’s biospecimen capabilities.